Court Bars Generic Zohydro Until 2034, Teva May Appeal

Teva Pharmaceutical Products Ltd.'s Actavis unit can’t sell its generic version of painkiller Zohydro ER in the U.S. until 2034 (Recro Gainesville LLC v. Actavis Laboratories FL, Inc., D. Del., 2017 BL 54293, No. 14-1118-GMS, 2/22/17).

The proposed generic infringes two patents for Zohydro ER capsules, a long-term opioid painkiller, and can’t be sold until those patents expire, Judge Gregory M. Sleet of the U.S. District Court for the District of Delaware ruled Feb. 22.

The ruling is good news for Pernix Therapeutics Holdings, the specialty pharmaceutical company that makes Zohydro ER, ...